ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    MK-3475-585
Previous Study | Return to List | Next Study

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03221426
Recruitment Status : Recruiting
First Posted : July 18, 2017
Last Update Posted : November 30, 2018
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 26, 2023
  Estimated Study Completion Date : July 26, 2023